- Home
- IONS vs ACT Comparison
IONS vs ACT Comparison
Compare IONS & ACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- ACT
- Stock Information
- Founded
- IONS 1989
- ACT 1981
- Country
- IONS United States
- ACT United States
- Employees
- IONS N/A
- ACT N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- ACT Specialty Insurers
- Sector
- IONS Health Care
- ACT Finance
- Exchange
- IONS Nasdaq
- ACT Nasdaq
- Market Cap
- IONS 6.8B
- ACT 5.5B
- IPO Year
- IONS 1991
- ACT 2021
- Fundamental
- Price
- IONS $69.15
- ACT $36.46
- Analyst Decision
- IONS Strong Buy
- ACT Hold
- Analyst Count
- IONS 18
- ACT 3
- Target Price
- IONS $72.83
- ACT $39.00
- AVG Volume (30 Days)
- IONS 2.2M
- ACT 500.2K
- Earning Date
- IONS 11-05-2025
- ACT 11-05-2025
- Dividend Yield
- IONS N/A
- ACT 2.28%
- EPS Growth
- IONS N/A
- ACT 6.06
- EPS
- IONS N/A
- ACT 4.41
- Revenue
- IONS $944,050,000.00
- ACT $1,223,030,000.00
- Revenue This Year
- IONS $24.01
- ACT $4.10
- Revenue Next Year
- IONS $4.06
- ACT $3.52
- P/E Ratio
- IONS N/A
- ACT $8.34
- Revenue Growth
- IONS 16.05
- ACT 3.15
- 52 Week Low
- IONS $23.95
- ACT $30.79
- 52 Week High
- IONS $69.25
- ACT $39.47
- Technical
- Relative Strength Index (RSI)
- IONS 80.12
- ACT 34.27
- Support Level
- IONS $61.03
- ACT $38.30
- Resistance Level
- IONS $63.18
- ACT $39.26
- Average True Range (ATR)
- IONS 1.63
- ACT 0.69
- MACD
- IONS 0.02
- ACT -0.29
- Stochastic Oscillator
- IONS 89.41
- ACT 7.07
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The principal mortgage insurance customers are originators of residential mortgage loans who determine which mortgage insurer or insurers will be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.